李佳, 吕良敬 . 靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022 , 21(03) : 299 -303 . DOI: 10.16150/j.1671-2870.2022.03.002
| [1] | Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs[J]. N Engl J Med, 2021, 385(7):628-639. |
| [2] | López-Benjume B, Rodríguez-Pintó I, Amigo MC, et al. Eculizumab use in catastrophic antiphospholipid syndrome(CAPS): Descriptive analysis from the "CAPS Re-gistry"[J]. Autoimmun Rev, 2022, 21(4):103055. |
| [3] | Chandwar K. Avacopan for the treatment of ANCA-associated vasculitis[J]. N Engl J Med, 2021, 384(21):e81. |
| [4] | Azoulay E, Russell L, van de Louw A, et al. Diagnosis of severe respiratory infections in immunocompromised patients[J]. Intensive Care Med, 2020, 46(2):298-314. |
| [5] | Bechman K, Halai K, Yates M, et al. Nonserious infections in patients with rheumatoid arthritis: results from the british society for rheumatology biologics register for rheumatoid arthritis[J]. Arthritis Rheumatol, 2021, 73(10):1800-1809. |
| [6] | Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry[J]. Ann Rheum Dis, 2010, 69(2):380-386. |
| [7] | Gottlieb AB, Deodhar A, Mcinnes IB, et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data[J]. Acta Derm Venereol, 2022, 102:adv00698. |
| [8] | Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management[J]. Br J Dermatol, 2017, 177(1):47-62. |
| [9] | Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis[J]. N Engl J Med, 2010, 363(3):221-232. |
| [10] | Iwata S, Saito K, Hirata S, et al. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus[J]. Lupus, 2018, 27(5):802-811. |
| [11] | 国家神经疾病医学中心, 国家传染病医学中心, 上海市医学会神经内科专科分会, 等. 抗CD20单克隆抗体治疗神经免疫相关疾病期间感染管理上海专家建议(2022)[J]. 中国临床神经科学, 2022, 30(1):1-7. |
| [11] | National Center for Neurological Disorders, National Medical Center for Infectious Diseases, Shanghai Medical Association Branch of Neurology, et al. Expert consensus on infection management for Anti-CD20 monoclonal antibody for the treatment of neuroimmune diseases(2022)[J]. Chin J Clin Neurosci, 2022, 30(1):1-7. |
| [12] | Md Yusof MY, Vital EM, McElvenny DM, et al. Predic-ting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases[J]. Arthritis Rheumatol, 2019, 71(11):1812-1823. |
| [13] | Konar M, Granoff DM. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults[J]. Blood, 2017, 130(7):891-899. |
| [14] | Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis[J]. Rheumatology (Oxford), 2019, 58(10):1755-1766. |
| [15] | Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel di-seases or other immune-mediated diseases: a systematic review and meta-analysis[J]. Gastroenterology, 2020, 158(6):1554-1573,e12. |
| [16] | Li J, Yu Y, Xie J, et al. Cryptococcal pneumonia in a patient with rheumatoid arthritis treated with baricitinib[J]. Rheumatology (Oxford), 2021, 61(1):e6-e7. |
| [17] | Valor-Méndez L, Voskens C, Rech J, et al. Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report[J]. Rheumatology (Oxford), 2021, 60(4):e122-e123. |
| [18] | Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases[J]. Ann Rheum Dis, 2020, 79(1):39-52. |
| [19] | Allen V, Longley N. Infections in immunosuppressed travellers with autoimmune inflammatory diseases-a narrative review and advice for clinical practice[J]. Rheumatology (Oxford), 2021, 60(9):3969-3976. |
| [20] | Friedman MA, Winthrop KL. Vaccines and disease-modi-fying antirheumatic drugs: practical implications for the rheumatologist[J]. Rheum Dis Clin North Am, 2017, 43(1):1-13. |
| [21] | Medeiros-Ribeiro AC, Bonfiglioli KR, Domiciano DS, et al. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis[J]. Ann Rheum Dis, 2022, 81(5):710-719. |
| [22] | Li J, Li J, Yu Y, et al. Pneumocystis pneumonia and rheumatic disease: diagnostic potential of circulating microbial cell-free DNA sequencing[J]. Rheumatol Adv Pract, 2021, 6(1):rkab105. |
| [23] | Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermato-logy clinical practice[J]. Autoimmun Rev, 2015, 14(6):503-509. |
| [24] | Galli M, Antinori S, Atzeni F, et al. Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis[J]. Clin Exp Rheumatol, 2017, 35(6):1018-1028. |
| [25] | Sun F, Chen Y, Wu W, et al. Varicella zoster virus infections increase the risk of disease flares in patients with SLE: a matched cohort study[J]. Lupus Sci Med, 2019, 6(1):e000339. |
/
| 〈 |
|
〉 |
